Adial Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Adial Pharmaceuticals has a total shareholder equity of $5.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $6.7M and $829.0K respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$5.20m |
| Equity | US$5.88m |
| Total liabilities | US$829.05k |
| Total assets | US$6.71m |
Recent financial health updates
Recent updates
Adial Clinical Trial: A Fluff Or A Win?
Aug 22Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01
Aug 16Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst
Jun 21Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate
Jan 11Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital
Nov 25Financial Position Analysis
Short Term Liabilities: ADIL's short term assets ($5.6M) exceed its short term liabilities ($829.0K).
Long Term Liabilities: ADIL has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ADIL is debt free.
Reducing Debt: ADIL had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADIL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ADIL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 10.5% each year